Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) – Pipeline Review, H2 2017’, provides in depth analysis on Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders under development targeting Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)

The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Chipscreen Biosciences Ltd

HitGen LTD

NatureWise Biotech & Medicals Corp

Sigma-Tau SpA

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Overview 6

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Companies Involved in Therapeutics Development 19

Chipscreen Biosciences Ltd 19

HitGen LTD 19

NatureWise Biotech & Medicals Corp 20

Sigma-Tau SpA 20

Zhejiang Hisun Pharmaceutical Co Ltd 21

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Drug Profiles 22

HG-3001 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

largazole - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

NBM-01 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecule to Inhibit HDAC 8 for Pancreatic Cancer - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ST-3595 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

tucidinostat - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Dormant Products 32

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC

3.5.1.98) - Product Development Milestones 33

Featured News & Press Releases 33

Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 33

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 34

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 34

Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program 35

Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 35

Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 36

Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China 36

Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 37

Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation 37

Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at “The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery” 38

Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China 38

Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year 38

Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China 39

Jan 23, 2010: Chidamide (CS055) won US FDA nod to enter into clinic trials in the US 39

Feb 26, 2009: Chidamide (CS055) won orphan drug designation from SFDA to enter into NDA-directed clinic study for CTCL 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 40

Disclaimer 41

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Chipscreen Biosciences Ltd, H2 2017 19

Pipeline by HitGen LTD, H2 2017 20

Pipeline by NatureWise Biotech & Medicals Corp, H2 2017 20

Pipeline by Sigma-Tau SpA, H2 2017 21

Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 21

Dormant Projects, H2 2017 32

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports